↓ Calculate your dosage
0
Placebo-Controlled RCTs
Zero double-blind placebo-controlled trials of synthetic Epithalon in humans. Most human data = open-label Russian cohort studies.
~150
Peer-Reviewed Papers
Published in PubMed as of 2025, primarily from a single Russian research group (Khavinson et al., St. Petersburg).
+16%
Lifespan Extension
Drosophila (fruit fly) mean lifespan in Khavinson's best animal series. Mice: ~12–27% in Anisimov cohorts.
$80–$250
Per Cycle Cost (US)
Licensed 503A compounding pharmacy. Research-use vials from gray-market vendors run $20–$50 — purity unverified.
Epithalon is a synthetic tetrapeptide (four amino acids: Ala-Glu-Asp-Gly) designed to mimic the pineal gland extract Epithalamin.
These are related but chemically distinct — Epithalamin is a crude bovine pineal extract containing multiple peptides; Epithalon (AEDG) is the purified synthetic version of the sequence identified as its active component.
Most of the animal and cell-line research is on synthetic Epithalon; the strongest human longevity cohort data (the Korkushko cardiovascular studies) actually used Epithalamin. This distinction is load-bearing for any evidence claim.
Mechanism 1
Telomerase +
In human fetal fibroblast cells, Epithalon induced telomerase expression — treated cells reached passage 44 vs. controls at the Hayflick limit (passage ~34). PMID 12937682 (2003, Khavinson). A 2025 independent study in Biogerontology (Al-Dulaimi et al.) confirmed dose-dependent telomere elongation in normal cells — and detected telomerase upregulation AND alternative lengthening (ALT) in two cancer cell lines (21NT, BT474). The latter finding is the active cancer-risk signal.
Mechanism 2
Pineal / Melatonin
Derived from pineal tissue, Epithalon appears to restore age-related decline in melatonin secretion. Small human studies (elderly cohorts) reported normalized melatonin circadian rhythm in Epithalamin-treated patients after biannual courses — consistent with its proposed pineal-bioregulatory mechanism.
Mechanism 3
Gene Expression
A 2020 study (Molecules, PMID 32019204) found AEDG peptide stimulated gene expression and protein synthesis during neurogenesis in vitro, with evidence suggesting an epigenetic mechanism — specifically interaction with histone proteins affecting chromatin accessibility. Cell-level finding only.
Mechanism 4
Antioxidant
Epithalamin reduced free-radical oxidation in both human patients and Drosophila in multiple 1995–2003 studies (Anisimov, Khavinson). Included human cancer patients (breast cancer; PMID 12926216) who showed reduced ROS in blood formed elements — uncontrolled, single-arm data.
How thick is each evidence layer? Nearly all controlled mechanistic work is animal or cell-line. Human data = cohort studies without placebo controls, from a single research group.
Animal / Preclinical
Mice, rats, Drosophila, in vitro cells. Lifespan, telomere, antioxidant, retinal. Strong mechanistic signal.
Human Cohort Studies
Open-label, non-placebo-controlled. Elderly populations in Russia. All from Khavinson/Korkushko group. Not independently replicated.
Placebo-Controlled RCT
Zero. The design gap is the fundamental limit of the Epithalon evidence base in 2026.
The preclinical library is large and consistent across three decades. Numbers are real; extrapolation to humans is your judgment call, not ours.
Drosophila Lifespan
+16%
Mean lifespan extension in fruit flies (Khavinson et al., Mechanisms of Ageing and Development, 2000). Separate Drosophila study reported similar results for the AEDG sequence specifically. Consistent across multiple fly cohorts.
Mouse Lifespan (Anisimov)
12–27%
Pineal peptide (Epithalamin) extended mean lifespan in CBA mice by ~12% and reduced spontaneous tumor incidence in female mice — with Anisimov's group separately citing up to 27% increase in certain strains. Mechanism: anti-tumor + antioxidant + hormonal. Note: female CBA mice are prone to spontaneous tumors; reduction in tumor rate is a confounding benefit in lifespan endpoints.
Cell Passage Limit (Human Fibroblasts)
+10 passages
In vitro: Epithalon-treated human fetal fibroblasts reached passage 44 before senescence; untreated controls hit the Hayflick limit at ~34 passages. Telomerase activation confirmed in the same cell line (PMID 15455129, 2004 follow-up). This is the most-cited single finding in longevity marketing — it is a cell study, not a person-level outcome.
Retinal Protection (Rat)
Preserved
Multiple rat studies (2002–2003) showed Epithalon preserved retinal photoreceptors in Campbell rats with hereditary retinal dystrophy, and slowed age-related retinal degeneration. This fed directly into the human retinitis pigmentosa study (PMID 12195242) — the model-to-human translation is among the most direct in the Epithalon literature.
Every known English-language human study. The designs are open-label cohort, not double-blind placebo-controlled. The Korkushko cardiovascular series used Epithalamin (crude extract), not synthetic AEDG — a critical distinction.
| # |
Study / PMID |
Type |
n |
Substance |
Outcome |
| 1 |
Korkushko et al. 2006 · PMID 17426848 — Bull Exp Biol Med; 12-year randomized clinical study in 79 elderly coronary patients |
Randomized clinical study (saline control reported; not double-blind) |
79 |
Epithalamin (crude pineal extract, NOT synthetic Epithalon) |
Positive — 28% fewer deaths overall; cardiovascular mortality ~2× lower vs control after long-term courses (abstract’s own wording) |
| 2 |
Korkushko et al. 2011 · PMID 22451889 — Bull Exp Biol Med; 15-year follow-up of the same Epithalamin cohort |
Randomized comparative follow-up |
79 |
Epithalamin |
Positive — Preserved physical endurance, normalized melatonin rhythm, carbohydrate/lipid markers; lower mortality signal carried forward. Still Epithalamin, not AEDG. |
| 3 |
Khavinson et al. 2002 · PMID 12195242 — Retinitis pigmentosa / degenerative retinal lesions pilot |
Open-label clinical |
Not stated in abstract |
Epithalon (synthetic AEDG) |
Positive — Authors report a "positive clinical effect" in 90% of treated patients vs baseline. No control group. High placebo risk. |
| 4 |
Khavinson et al. 2003 · PMID 12937682 + Al-Dulaimi 2025 · PMID 40908429 — Telomere / telomerase work |
Cell culture (not an in-person telomere trial) |
Cell lines |
Epithalon (synthetic) |
Mechanistic — Telomerase + longer telomeres in human cells (2003); 2025 independent lab confirmed elongation in normal cells and ALT activity in two breast-cancer lines. No PubMed-indexed primary paper was found for measured telomere lengthening in living elderly humans — a review (PMID 12374906, "Peptides and Ageing") is often mis-cited as that study and is not used that way here. |
| 5 |
Khavinson et al. 2001 · PMID 11524632 — Neuroendocrine in senescent monkeys |
Primate model |
Primates |
Epithalon |
Positive — Restored disturbed neuroendocrine regulation in old monkeys. Bridge species between rodents and humans — still not a human outcome trial. |
| 6 |
Araj et al. 2025 · PMID 40141333 — Comprehensive review (Medical University of Gdańsk) |
Review |
N/A |
Epithalon (review) |
Review — Calls Epitalon "highly bioactive" with promising properties; first major review from outside the Russian institute. Explicitly acknowledges the human-data gap. |
Reality check (honest reading): The strongest human mortality signal — Korkushko 2006/2011 showing 28% fewer overall deaths and ~2× lower cardiovascular mortality — used Epithalamin (crude pineal extract), not synthetic Epithalon. Related compounds, not identical. That study was randomized with a saline control (PubMed indexes it as an RCT) but not an independent Western replication, and it was not double-blind. Evidence for synthetic AEDG in living humans is limited to small open-label clinical observations (e.g. retinal pilot). Cell-line telomere work is real (2003 + 2025 independent lab) and is not the same as measured telomere lengthening in elderly people. ClinicalTrials.gov: no registered trials found (July 2026).
What does Epithalon actually cost compared to what else a longevity-minded person might spend money on? All prices are 2026 US market.
Research Use
Epithalon (Compounded 503A)
$80–$250
per 10 mg vial · $300–$1,200/year
10–20 day cycles, 1–2× per year
Most Human RCTs
NMN / NR Supplements
$40–$80
per month · ~$480–$960/year
Daily oral — 15+ RCTs (metabolic endpoints)
FDA-Approved Drug
Rapamycin (Compounded Sirolimus)
$80–$250
per month · requires labs & Rx
3–6 mg weekly · strongest animal longevity data
TA-65 (Oral Telomerase Activator)
$200–$600
per month · $2,400–$7,200/year
Daily oral — 1 pilot RCT; most expensive class option
Exercise (150 min/wk, moderate)
$0
zero direct cost
About 19% lower all-cause mortality at 150–299 min/wk of moderate activity — not a third · 116,221-person prospective cohort (Circulation 2022)
💰 Follow the Money
Epithalon is a four-amino-acid sequence — cheap to synthesize, unpatentable. This means no pharmaceutical company can profit from running the $50M+ definitive human RCT. "No large trial exists" is a funding finding, not a scientific verdict. The research that does exist was conducted by Russian government-affiliated scientists, largely outside the US/EU pharma funding stream — which is why it's largely invisible in Western media despite being published in PubMed.
Compare to TA-65, a patented oral telomerase activator from a single company at $200–$600/month. It also lacks large RCTs, yet carries no comparable suppression label in mainstream media — likely because its commercial sponsor is US-based. The evidence standard applied to Epithalon and TA-65 in the US press has not been consistent.
No FDA-approved dosing exists. Daily subcutaneous tiers below are the patterns most often reported in US clinic and telehealth write-ups for synthetic Epithalon — labeled COMMUNITY, not trial doses. The only long-term human mortality study used Epithalamin at a different schedule (10 mg intramuscular every 3 days × 5 injections per course, 6 courses over 3 years). Active malignancy is a hard contraindication across practitioner sources (telomerase concern).
Conservative / Entry
5 mg/day SC
10–14 days per cycle · often 1 cycle/year · lower end of reported synthetic protocols
Standard Longevity
10 mg/day SC
10–20 days per cycle · 1–2 cycles/year · most commonly reported US practitioner pattern for synthetic AEDG
Intranasal Alternative
200–400 mcg
2× daily intranasal · 20–30 days · used by some as an injection alternative; bioavailability not rigorously established
Epithalamin RCT schedule (different compound)
10 mg IM q3d × 5
Per course, 6 courses over 3 years — the Korkushko 2006/2011 dosing for Epithalamin extract (PMID 17426848). Shown so readers do not confuse that trial’s intramuscular course with modern daily SC synthetic protocols.
TRIAL (extract)
Hard Contraindication
STOP
Active cancer / active malignancy. Telomerase activation is a theorized mechanism that could support cancer-cell telomere maintenance. Practitioner sources treat this as an absolute stop. Personal or strong family history of cancer = oncology consult before any Epithalon use.
SAFETY GATE
The regulatory picture is actively evolving in 2026 — faster than for most peptides. Status as of July 28, 2026. Primary sources quoted below.
FDA / PCAC — July 2026
PCAC Recommended (Advisory Only)
On
July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted
7–5 (one abstention) to recommend Epithalon for the 503A Bulk Drug Substances list. This is an advisory recommendation — it does NOT immediately legalize compounding. The FDA must conduct notice-and-comment rulemaking (typically 12–24 months) before formal listing. FDA review staff had recommended against listing all seven peptides reviewed.
Prior history:
September 2023 — FDA placed Epithalon in Category 2 ("significant safety concerns" cited: immunogenicity, impurities, limited human data).
April 15, 2026 — HHS Secretary RFK Jr. removed Epithalon and 11 other peptides from Category 2 after nominators withdrew. Removal from Category 2 ≠ authorization to compound.
FDA's own published language:
"Removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A."
→ McDermott Law PCAC summary ·
→ Peptide Catalog vote tracker
Current Legal Status (US)
Not Approved · Gray Zone
Epithalon is
not FDA-approved as a drug. It is not a permitted dietary supplement ingredient under DSHEA. As of July 2026: it is no longer in Category 2 (no longer actively prohibited from nomination) but is not yet on the Category 1 / 503A permitted list. The 503A compounding pathway remains legally ambiguous pending rulemaking.
503A pharmacies currently operate in a gray zone: some compound it on physician prescription under a clinical-judgment interpretation; others decline pending formal listing. Research-use-only vials from unregulated vendors (online, overseas) are sold without prescription — these carry zero quality assurance and the FDA has documented contamination cases in this product class.
→ PepScribe legal status breakdown
WADA / Sports
Not Scheduled
Epithalon does not appear on WADA's 2026 Prohibited List. It is not classified as a prohibited peptide hormone, growth factor, or mimetic in the current WADA code. However, any peptide with anabolic or endurance effects may fall under the S0 (non-approved substances) or S2 catch-all categories — athletes using Epithalon should obtain a specific ruling from their governing body before competition.
→ WADA Prohibited List 2026
🏛️ The Suppression / Incentive Record — Precisely Stated
September 2023 FDA Category 2 placement: The FDA cited "significant safety concerns" for Epithalon and 12+ peptides, without publishing detailed mechanistic reasoning for each. The batch categorization covered compounds with widely varying evidence profiles — critics noted the Category 2 designation grouped Epithalon (with 150+ papers and decades of human observation) with compounds that had near-zero published data. No FDA warning letter specifically targeting an Epithalon practitioner was found in our Pass 4 search.
The precise incentive claim: Epithalon is a four-amino-acid sequence with no patent protection and negligible manufacturing cost. No pharmaceutical company could recoup a $50M+ phase 3 trial investment from it. This is a structural funding barrier — not a conspiracy, but an economic reality. "No large trial exists" and "it doesn't work" are different sentences; the evidence base suggests the former, not the latter.
RFK Jr. involvement (April 2026): The removal of Epithalon from Category 2 was not a scientific approval but a regulatory deprioritization following HHS Secretary Kennedy's stated policy of expanding peptide access. The PCAC's subsequent 7–5 favorable vote followed — FDA staff had recommended against all seven peptides. These facts are primary-record, not a summary.
Two equal pillars — the controlled literature vs. credentialed clinicians who have addressed Epithalon on record. Both shown at equal weight. Disagreements shown plainly.
📚 What PubMed Shows
Telomerase activation confirmed in human fibroblasts in vitro (PMID 12937682). A 2025 independent study (Al-Dulaimi, Biogerontology, DOI 10.1007/s10522-025-10315-x) confirmed telomere elongation in normal cells AND flagged ALT pathway activation in cancer cell lines — the only substantive Western replication to date.
The strongest human longevity data (50% lower CV mortality over 12 years) used Epithalamin, not synthetic Epithalon. The two are related but not identical. This distinction is absent from most commercial discussions.
All human studies originate from one institution. No independent replication. No placebo-controlled trial. Khavinson (1946–2024) was a legitimate MD/DSc with 700+ papers and ORCID 0000-0001-7547-7725 — a serious scientist, not a fringe figure, though single-group monopoly on evidence is a recognized limitation.
The 2025 comprehensive review (Araj et al., PMID 40141333) — the first major review from outside Russia — called Epithalon "highly bioactive" with "promising properties" while acknowledging the human data gap.
🩺 What Practitioners Report
Dr. Alex Tatem (MD) — verified
YouTube: "The Fountain of Youth Peptide? The Truth About Epitalon" (2026-06-16 · 44,754 views · 25:48). Position: "fascinating tool" — telomere/epigenetic effects are real in cell studies; human evidence thin but mechanism compelling enough for advanced longevity stacking. Discloses no commercial product interest in the video. Credential verified: MD per channel self-disclosure; independent board/licensing record not accessible for verification from public sources — flag accordingly.
Pass 3 — Practitioners using it with patients: No verified case series, clinic outcome reports, or published treatment records from named licensed US/Western clinicians who gave Epithalon to documented patient cohorts and published results were found in our search. The Russian Khavinson group (Prof. Khavinson, MD DSc, Director St. Petersburg Institute 1992–2024 — credential: khavinson.info/curriculum-vitae, ORCID verified) conducted the foundational human observations, but their studies fall in the category of research rather than clinical practice reporting. This absence is itself informative and honestly reported.
Real-World Use
Community sentiment (Reddit longevity threads, biohacking forums): Epithalon is one of the more credibly-discussed peptides in longevity circles, precisely because it has actual PubMed citations. Common reported anecdotes: improved sleep quality, sense of restoration, subtle energy improvement over 10–20 day cycles. No verified case series from this community. The sleep/circadian angle (melatonin restoration) is the most consistently reported subjective effect and is mechanistically plausible given Epithalon's pineal origin.
Removal asymmetry — Pass 8 note: In our yt-dlp search, no practitioner videos about Epithalon were found to have been removed (unlike some BPC-157 or peptide competitor content). The Epithalon media landscape appears to be primarily educational/explanatory content with no documented removal campaigns. This may reflect that Epithalon's current regulatory gray zone has not yet attracted the same level of institutional pushback as compounds more directly competing with approved pharmaceuticals.
Cancer Risk — the Central Concern
Theorized
Telomerase reactivation is a hallmark of cancer cell immortality. The 2025 Al-Dulaimi study (Biogerontology) detected Epithalon-driven ALT (alternative lengthening of telomeres) pathway activity in breast cancer cell lines 21NT and BT474. This is in vitro; it does NOT prove Epithalon causes cancer in humans. However, it is the mechanistic signal that makes active malignancy an absolute contraindication in all practitioner protocols. Long-term human data on cancer incidence in Epithalon users does not exist.
Injection Site Reactions
Reported
Subcutaneous injection reactions (mild redness, irritation) are the most commonly reported side effect. No systematic safety reporting has been published for synthetic Epithalon in humans. The absence of documented serious adverse events is partly attributable to the absence of large, monitored trials.
→ T4 clinic consensus · no primary safety trial
Known Toxicity Profile
Minimal (known)
No organ toxicity, overdose signal, or drug-interaction alert was found in PubMed or openFDA for Epithalon. openFDA returns no label (no approved drug). The Khavinson research group never reported serious adverse events across their multi-decade human cohort work — but cohort sizes are small and monitoring was not standardized. "No known toxicity" is bounded: it means no documented signal in a limited dataset, not a clean bill of health.
→ openFDA: no label · PubMed safety search: no adverse event papers found
Sourcing / Purity Risk
HIGH (gray-market)
The majority of Epithalon sold online ($20–$50 vials) is research-use-only with no verified sterility, endotoxin testing, or accurate concentration. FDA has documented contamination in this product class. A $20 vial cannot cover the cost of USP <71> sterility testing (~$150–$400/batch). Sub-$30 injectable Epithalon is effectively an unknown compound. This is the most concrete near-term safety risk for anyone using it.
⛔ Hard safety gates for anyone considering Epithalon: (1) Active cancer or active cancer treatment — do not use. (2) Strong family history of cancer — oncology consultation before use. (3) Auto-immune conditions — no data; discuss with your physician. (4) Pregnancy or breastfeeding — no safety data. (5) Use only pharmaceutical-grade material from a verified 503A compounding pharmacy with a Certificate of Analysis.
✓ What seems reassuring (provisionally): Across decades of use by what appears to be hundreds to thousands of research participants and early adopters, no organ toxicity, no published serious adverse event, and no overdose case has been documented. This is a thin evidence base — but the absence of a safety signal over 30 years of research-context use is not nothing. It suggests that short-course cyclical Epithalon at the studied doses is unlikely to carry acute toxicity risks comparable to, say, systemic immunosuppressants or high-dose steroids. The unknown is long-term cancer risk, which cannot be resolved without large-scale, long-term human studies.
An honest read of Epithalon in 2026
What it is: A synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) derived from the pineal gland's natural bioregulatory peptide, Epithalamin. It is the most scientifically documented of the longevity peptides — with 150+ PubMed papers — but also one of the most misrepresented, because marketers routinely conflate cell-line data ("Epithalon extended cells past the Hayflick limit") with human outcomes ("Epithalon extends human lifespan"). Those are different claims. One is proven in a dish; the other is not proven at all.
Who's using it: Longevity-focused physicians, biohackers, and peptide clinics (primarily in Russia for decades; expanding to US as regulatory access evolves). The typical US user is someone willing to tolerate research-stage interventions — either through a gray-market purchase or, more properly, a 503A pharmacy under physician supervision. As of July 2026, a PCAC favorable vote has been logged but compounding is not formally authorized pending rulemaking. A sub-$80 vial without a Certificate of Analysis is not pharmaceutical-grade Epithalon.
What the law says: Not FDA-approved. Not a legal supplement. After the PCAC's July 24, 2026 7–5 favorable vote, a formal compounding pathway is closer but not yet open — rulemaking typically takes 12–24 months. The gray-market research-use-only channel is unregulated and carries real purity risk. The Category 2 restriction was lifted in April 2026; current status is "pending rulemaking." This is legitimately one of the most active regulatory moments for this compound since its Western introduction.
What the research shows: The mechanism is credible and confirmed in vitro (telomerase activation, telomere elongation in normal human cells, epigenetic gene expression effects). The animal lifespan data is real and consistent across multiple species. The human evidence is limited — all from one Russian research group, with no placebo controls and no independent replication in Western populations. The strongest outcome data (50% lower cardiovascular mortality over 12 years) was obtained with Epithalamin, not synthetic Epithalon. The 2025 Al-Dulaimi study adds independent confirmation of the telomere mechanism AND a cancer-cell-line safety signal that deserves serious attention. Net: promising signal, thin human evidence, meaningful cancer-risk theoretical concern, sourcing/purity risk if outside pharmaceutical channels.
- The telomere mechanism is real — confirmed independently in 2025. The cancer cell-line finding from that same study is a genuine caution, not a headline to ignore.
- The best human longevity data (Korkushko 12-year cardiovascular series) used Epithalamin (crude extract) — not synthetic Epithalon. Do not conflate these compounds' evidence.
- Zero placebo-controlled RCTs for synthetic Epithalon in humans. "No large trial" = a funding problem, not proof of failure. The compound is unpatentable; nobody profits from the $50M definitive trial.
- If you're cancer-free and cancer-risk-clear and choose to use it: pharmaceutical-grade only, 503A compounding pharmacy, Certificate of Analysis mandatory, physician supervision recommended.
- The regulatory gate is moving — the PCAC vote is the most significant US regulatory development for Epithalon since 2023. Watch for FDA rulemaking in 2027.
- Not medical advice. Discuss any experimental intervention with your physician — especially if you have personal or family cancer history.